MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-07-2026
Jaguar Health DPO Ratio 2011-2026 | JAGX
Annual DPO Ratio Jaguar Health
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 676 | 958 | 966 | 971 | 758 | 530 | 512 | 715 | 3.05 K | 3.63 K | 1.7 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.63 K | 512 | 1.31 K |
Quarterly DPO Ratio Jaguar Health
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.29 K | 1.18 K | 1.03 K | 729 | 792 | 897 | 870 | 962 | 1.52 K | - | 888 | 936 | 866 | - | 644 | 664 | 743 | - | 554 | 421 | 682 | - | 515 | 388 | 568 | - | 671 | 813 | 1.26 K | - | 3.25 K | 27.1 K | 22.2 K | - | 4.79 K | 5.46 K | 2.71 K | - | 1.43 K | 3.09 K | 1.69 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 27.1 K | 388 | 2.78 K |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acorda Therapeutics
ACOR
|
277 | - | -24.86 % | $ 820 K |  USA |
 |
Alnylam Pharmaceuticals
ALNY
|
55 | $ 326.56 | -2.05 % | $ 42.8 B | USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 21.48 | -0.92 % | $ 1 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
ContraFect Corporation
CFRX
|
1.83 K | - | -5.16 % | $ 5.39 M | USA |
 |
Akebia Therapeutics
AKBA
|
168 | $ 1.41 | -9.12 % | $ 363 M | USA |
 |
Aquestive Therapeutics
AQST
|
395 | $ 4.16 | -1.89 % | $ 445 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 24.22 | -1.46 % | $ 3.08 B | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.48 | -0.67 % | $ 394 M | Britain |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Caladrius Biosciences
CLBS
|
51.2 | - | -16.75 % | $ 25.8 M | USA |
 |
Clearside Biomedical
CLSD
|
1.67 K | - | - | $ 25.3 M | USA |
 |
Celldex Therapeutics
CLDX
|
4.06 K | $ 33.53 | -1.0 % | $ 2.23 B | USA |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | Britain |